Inhibitor Therapeutics FY2025 operating loss rises to $3.3 million; interest income drops 66.67% to $0.1 million

Reuters03-26 18:04

Inhibitor <a href="https://laohu8.com/S/LENZ">Therapeutics</a> FY2025 operating loss rises to $3.3 million; interest income drops 66.67% to $0.1 million

Inhibitor Therapeutics published its annual report on Form 10-K.
Net loss was USD 3.3 million and operating cash flow was negative USD 3.2 million.
Research and development expense fell 5.56% to USD 1.7 million, driven by lower internal personnel costs tied to the relative significance of R&D activity and developments during the year.
General and administrative expense decreased 10.53% to USD 1.7 million, reflecting lower compensation costs and insurance costs.
Management said it expects additional losses and that liquidity is insufficient for the next 12 months, and noted a registered direct offering agreement for USD 3.0 million in proceeds intended for working capital and general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibitor Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-012751), on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622855234?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 18:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622855234","market":"us","top_or_hot":-1,"title":"Inhibitor Therapeutics FY2025 operating loss rises to $3.3 million; interest income drops 66.67% to $0.1 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Inhibitor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> FY2025 operating loss rises to $3.3 million; interest income drops 66.67% to $0.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Inhibitor Therapeutics published its annual report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>.\n        </li>\n<li>\n          Net loss was USD 3.3 million and operating cash flow was negative USD 3.2 million.\n        </li>\n<li>\n          Research and development expense fell 5.56% to USD 1.7 million, driven by lower internal personnel costs tied to the relative significance of R&amp;D activity and developments during the year.\n        </li>\n<li>\n          General and administrative expense decreased 10.53% to USD 1.7 million, reflecting lower compensation costs and insurance costs.\n        </li>\n<li>\n          Management said it expects additional losses and that liquidity is insufficient for the next 12 months, and noted a registered direct offering agreement for USD 3.0 million in proceeds intended for working capital and general corporate purposes.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/INTI\">Inhibitor Therapeutics Inc.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-012751), on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inhibitor Therapeutics FY2025 operating loss rises to $3.3 million; interest income drops 66.67% to $0.1 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInhibitor Therapeutics FY2025 operating loss rises to $3.3 million; interest income drops 66.67% to $0.1 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 18:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Inhibitor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> FY2025 operating loss rises to $3.3 million; interest income drops 66.67% to $0.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Inhibitor Therapeutics published its annual report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>.\n        </li>\n<li>\n          Net loss was USD 3.3 million and operating cash flow was negative USD 3.2 million.\n        </li>\n<li>\n          Research and development expense fell 5.56% to USD 1.7 million, driven by lower internal personnel costs tied to the relative significance of R&amp;D activity and developments during the year.\n        </li>\n<li>\n          General and administrative expense decreased 10.53% to USD 1.7 million, reflecting lower compensation costs and insurance costs.\n        </li>\n<li>\n          Management said it expects additional losses and that liquidity is insufficient for the next 12 months, and noted a registered direct offering agreement for USD 3.0 million in proceeds intended for working capital and general corporate purposes.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/INTI\">Inhibitor Therapeutics Inc.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-012751), on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL8NdxCT:1","article_id":"2622855234","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622855234","pubTimestamp":1774519475,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Inhibitor Therapeutics published its annual report on Form 10-K.Net loss was USD 3.3 million and operating cash flow was negative USD 3.2 million.Research and development expense fell 5.56% to USD 1.7 million, driven by lower internal personnel costs tied to the relative significance of R&D activity and developments during the year.General and administrative expense decreased 10.53% to USD 1.7 million, reflecting lower compensation costs and insurance costs.Management said it expects additional losses and that liquidity is insufficient for the next 12 months, and noted a registered direct offering agreement for USD 3.0 million in proceeds intended for working capital and general corporate purposes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or lega","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK7096":"制药","BK4139":"生物科技","INTI":"Inhibitor Therapeutics Inc.","MYX.AU":"MAYNE PHARMA GROUP LTD"},"translate_title":"Inhibitor Therapeutics 2025财年运营亏损增至330万美元；利息收入下降66.67%至10万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYX.AU":0.9,"INTI":0.9},"content_text":"Inhibitor Therapeutics FY2025 operating loss rises to $3.3 million; interest income drops 66.67% to $0.1 million\n    \n\n\n          Inhibitor Therapeutics published its annual report on Form 10-K.\n        \n\n          Net loss was USD 3.3 million and operating cash flow was negative USD 3.2 million.\n        \n\n          Research and development expense fell 5.56% to USD 1.7 million, driven by lower internal personnel costs tied to the relative significance of R&D activity and developments during the year.\n        \n\n          General and administrative expense decreased 10.53% to USD 1.7 million, reflecting lower compensation costs and insurance costs.\n        \n\n          Management said it expects additional losses and that liquidity is insufficient for the next 12 months, and noted a registered direct offering agreement for USD 3.0 million in proceeds intended for working capital and general corporate purposes.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibitor Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-012751), on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622855234","isCrawlerRequest":true}